Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy

R. Hakl, P. Kuklínek, I. Krčmová, P. Králíčková, T. Freiberger, P. Janků, M. Vlková, J. Litzman,

. 2018 ; 38 (7) : 810-815. [pub] 20181002

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045212

Grantová podpora
NV15-28732A MZ0 CEP - Centrální evidence projektů
NV16-34414A MZ0 CEP - Centrální evidence projektů

PURPOSE: Hereditary angioedema (HAE) is a rare disease caused by a C1 inhibitor (C1-INH) deficit. Clinically, HAE is manifested by repeated episodes of localized subcutaneous or submucosal oedema attacks. Managing HAE patients in pregnancy is challenging, since there are only limited data on the safety and efficacy of various therapeutic approaches. METHODS: We present our clinical experience treating acute HAE attacks during pregnancy in six consecutive patients. RESULTS: During the pregnancies, 79 HAE attacks occurred. The most frequent were abdominal 53 (67.1%) followed by peripheral 21 (26.6%), facial 10 (12.7%), and laryngeal 10 (12.7%) oedemas; 13 (16.5%) attacks were combined. Fifty (63.3%) attacks were treated with recombinant human C1-INH (rhC1-INH); 17 (21.5%) with plasma-derived, pasteurized, nanofiltered C1-INH (pnfC1-INH); 13 (16.5%) with icatibant; and 1 (1.3%) with plasma-derived, nanofiltered C1-INH (nfC1-INH). Treatment had to be repeated in 5 attacks (6.3%). All six deliveries (one caesarean section and five spontaneous vaginal deliveries) were complication free. All pregnancies went to the full term and the patients delivered healthy babies with a birth weight ranging from 2850 to 3690 g. No congenital abnormalities were detected in the neonates. No abortions occurred. CONCLUSIONS: Our results show good C1-INH or icatibant treatment efficacy for HAE attacks in pregnancy. The treatment by the first drug used was effective in 93.7% of all attacks. In 6.3% of attacks, a second treatment had to be used. No adverse effects were observed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045212
003      
CZ-PrNML
005      
20201023093858.0
007      
ta
008      
200109s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10875-018-0553-4 $2 doi
035    __
$a (PubMed)30280305
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Hakl, Roman $u Department of Clinical Immunology and Allergology, St. Anne's University Hospital in Brno, Brno, Czech Republic. roman.hakl@fnusa.cz. Faculty of Medicine, Masaryk University, Brno, Czech Republic. roman.hakl@fnusa.cz.
245    10
$a Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy / $c R. Hakl, P. Kuklínek, I. Krčmová, P. Králíčková, T. Freiberger, P. Janků, M. Vlková, J. Litzman,
520    9_
$a PURPOSE: Hereditary angioedema (HAE) is a rare disease caused by a C1 inhibitor (C1-INH) deficit. Clinically, HAE is manifested by repeated episodes of localized subcutaneous or submucosal oedema attacks. Managing HAE patients in pregnancy is challenging, since there are only limited data on the safety and efficacy of various therapeutic approaches. METHODS: We present our clinical experience treating acute HAE attacks during pregnancy in six consecutive patients. RESULTS: During the pregnancies, 79 HAE attacks occurred. The most frequent were abdominal 53 (67.1%) followed by peripheral 21 (26.6%), facial 10 (12.7%), and laryngeal 10 (12.7%) oedemas; 13 (16.5%) attacks were combined. Fifty (63.3%) attacks were treated with recombinant human C1-INH (rhC1-INH); 17 (21.5%) with plasma-derived, pasteurized, nanofiltered C1-INH (pnfC1-INH); 13 (16.5%) with icatibant; and 1 (1.3%) with plasma-derived, nanofiltered C1-INH (nfC1-INH). Treatment had to be repeated in 5 attacks (6.3%). All six deliveries (one caesarean section and five spontaneous vaginal deliveries) were complication free. All pregnancies went to the full term and the patients delivered healthy babies with a birth weight ranging from 2850 to 3690 g. No congenital abnormalities were detected in the neonates. No abortions occurred. CONCLUSIONS: Our results show good C1-INH or icatibant treatment efficacy for HAE attacks in pregnancy. The treatment by the first drug used was effective in 93.7% of all attacks. In 6.3% of attacks, a second treatment had to be used. No adverse effects were observed.
650    _2
$a dospělí $7 D000328
650    _2
$a hereditární angioedémy $x diagnóza $x farmakoterapie $x genetika $7 D054179
650    _2
$a antiflogistika nesteroidní $x terapeutické užití $7 D000894
650    _2
$a bradykinin $x analogy a deriváty $x terapeutické užití $7 D001920
650    _2
$a inhibiční protein komplementu C1 $x aplikace a dávkování $x terapeutické užití $7 D050718
650    _2
$a vedení porodu $7 D036861
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a těhotenství $7 D011247
650    12
$a komplikace těhotenství $7 D011248
650    _2
$a trimestry těhotenství $7 D011264
650    _2
$a rekombinantní proteiny $x aplikace a dávkování $x terapeutické užití $7 D011994
650    _2
$a rizikové faktory $7 D012307
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kuklínek, Pavel $u Department of Clinical Immunology and Allergology, St. Anne's University Hospital in Brno, Brno, Czech Republic.
700    1_
$a Krčmová, Irena $u Department of Clinical Immunology and Allergy, University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Králíčková, Pavlína $u Department of Clinical Immunology and Allergy, University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Freiberger, Tomáš $u Department of Clinical Immunology and Allergology, St. Anne's University Hospital in Brno, Brno, Czech Republic. Faculty of Medicine, Masaryk University, Brno, Czech Republic. Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic.
700    1_
$a Janků, Petr $u Department of Obstetrics and Gynecology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Vlková, Marcela $u Department of Clinical Immunology and Allergology, St. Anne's University Hospital in Brno, Brno, Czech Republic. Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Litzman, Jiří $u Department of Clinical Immunology and Allergology, St. Anne's University Hospital in Brno, Brno, Czech Republic. Faculty of Medicine, Masaryk University, Brno, Czech Republic.
773    0_
$w MED00002589 $t Journal of clinical immunology $x 1573-2592 $g Roč. 38, č. 7 (2018), s. 810-815
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30280305 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20201023093856 $b ABA008
999    __
$a ok $b bmc $g 1483481 $s 1083885
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 38 $c 7 $d 810-815 $e 20181002 $i 1573-2592 $m Journal of clinical immunology $n J Clin Immunol $x MED00002589
GRA    __
$a NV15-28732A $p MZ0
GRA    __
$a NV16-34414A $p MZ0
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Možnosti archivace